ITGB7 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1413014	1.00	20/20
SCHEMBL1413023	1.00	20/20
SCHEMBL1413026	1.00	20/20
SCHEMBL1413032	1.00	20/20
SCHEMBL1413038	1.00	20/20
SCHEMBL1413057	1.00	20/20
SCHEMBL1413059	1.00	20/20
SCHEMBL1413068	1.00	20/20
SCHEMBL1413088	1.00	20/20
SCHEMBL1413095	1.00	20/20
SCHEMBL1413096	1.00	20/20
SCHEMBL1413105	1.00	20/20
SCHEMBL1413108	1.00	20/20
SCHEMBL1413123	1.00	20/20
SCHEMBL1413143	1.00	20/20
SCHEMBL1413151	1.00	20/20
SCHEMBL1413048	0.98	20/20
SCHEMBL1413053	0.90	20/20
SCHEMBL1413058	0.88	20/20
SCHEMBL1413012	0.88	20/20

Clinical trials — most relevant to ITGB7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease	PHASE4	COMPLETED
68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Angiogenesis in Ischemic Heart Disease	PHASE2	UNKNOWN
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer	PHASE1/PHASE2	COMPLETED
A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I	PHASE1	WITHDRAWN
Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption	PHASE1	COMPLETED
Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors	PHASE1	COMPLETED
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants	PHASE1	COMPLETED
68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis	EARLY_PHASE1	UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis	EARLY_PHASE1	UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma	EARLY_PHASE1	UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Stroke	EARLY_PHASE1	UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients	EARLY_PHASE1	UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Myocardial Infarction	EARLY_PHASE1	UNKNOWN
An Open-label, Single-arm, Single-center Study to Evaluate the Diagnostic Efficacy of a Novel PET Probe, 68Ga-SFB6-ZN01, in Patients With Malignant Tumors	EARLY_PHASE1	NOT_YET_RECRUITING
99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients	EARLY_PHASE1	COMPLETED
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis	nan	UNKNOWN
Angiogenesis and Fibrosis in Aortic Stenosis	nan	COMPLETED
Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)	nan	COMPLETED
Angiogenesis and Fibrosis in Myocardial Infarction	nan	COMPLETED
Potential Role of microRNA 410 and BIRC7 Pathways in Recurrent Spontaneous Miscarriage	nan	COMPLETED
IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer Types	nan	COMPLETED
Clinical Study of 18F-FAPI-RGD in Ovarian Cancer	nan	COMPLETED
Early Regenerative Intervention for Post-Traumatic Osteoarthritis	nan	UNKNOWN
Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis	nan	COMPLETED
The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications	nan	COMPLETED
Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA)	nan	UNKNOWN
Eosinophil Induced Remodelling in Asthma	nan	COMPLETED
Clinical Study of 18F-FAPI-RGD in Breast Tumors	nan	COMPLETED
the Long-term Retention Rate and Influence Factors of Individualized Treatment of Vedolizumab in Ulcerative Colitis	nan	COMPLETED
ITGA2b and SELP Expression in Cancer Pancreas and Biliary Tract Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ITGB7 binder may also engage these)

Protein	Name	Similarity
P26011	—	1.000	P26011 →
ITGB4	Integrin beta-4	0.988	landscape →
Q6AYF4	—	0.985	Q6AYF4 →
A2A863	—	0.985	A2A863 →
ITGB2	Integrin beta-2	0.984	landscape →
P58459	—	0.983	P58459 →
Q9H324	—	0.983	Q9H324 →
Q3UH93	—	0.982	Q3UH93 →
Q8BNJ2	—	0.981	Q8BNJ2 →
Q9Z0T9	—	0.981	Q9Z0T9 →
Q9C0C4	—	0.981	Q9C0C4 →
P0C0K6	—	0.981	P0C0K6 →
Q9TT93	—	0.981	Q9TT93 →
P32592	—	0.981	P32592 →
Q1RPR6	—	0.980	Q1RPR6 →
Q0V8J4	—	0.980	Q0V8J4 →
Q9Z143	—	0.980	Q9Z143 →
Q9DBX3	—	0.980	Q9DBX3 →
P70208	—	0.980	P70208 →
Q13751	—	0.980	Q13751 →
ADAMTS7	A disintegrin and metalloproteinase with thrombospondin motifs 7	0.980	landscape →
P51805	—	0.980	P51805 →
P0C0K7	—	0.980	P0C0K7 →
Q9Y6F9	—	0.980	Q9Y6F9 →
Q61087	—	0.979	Q61087 →
Q9UGT4	—	0.979	Q9UGT4 →
INSRR	Insulin receptor-related protein	0.979	landscape →
Q64632	—	0.979	Q64632 →
Q6ECI6	—	0.979	Q6ECI6 →
Q12891	—	0.979	Q12891 →